Neuralink enters 2026 as the clear leader in brain-computer interface development, having achieved clinical validation, international expansion, and substantial capital raising. The company's main opportunity lies in rapidly increasing BCI power through its 'Moore's Law for neurons' concept, with plans to increase electrode density from 1,024 to 3K by 2026, 10K by 2027, and over 25K by 2028 to enable advanced applications like real-time speech decoding. Neuralink projects $1 billion in annual revenue by 2031 through three product lines: Telepathy, Blindsight, and Deep, with targets of 2,000 Telepathy procedures by 2029 and 10,000 Blindsight procedures by 2030.
Cyborg Score Rationale
Two FDA Breakthrough designations and international regulatory approvals establish Neuralink at the forefront of transformative medical technology. The company plans high-volume production and almost entirely automated surgical procedures in 2026. However, the company has faced criticism for euthanizing primates during medical trials, with records showing complications with surgically implanted electrodes.
Top Insights
Neuralink achieved speech translation capabilities as of March 2026, with patients playing complex games like World of Warcraft using mind control
The company raised $650 million in Series E funding on May 27, 2025, with total cumulative funding reaching $1.29 billion across 6 rounds
The Blindsight vision-restoration program received FDA 'breakthrough' status, accelerating development to enable blind individuals with intact visual cortex to regain some vision
As of September 2025, 12 patients across multiple countries had received implants and demonstrated ability to control both digital and physical devices via brain signals
Named Competitors
Synchron — Non-invasive BCI using blood vessel electrodes
Precision Neuroscience — Surface electrode BCIs for reduced brain damage
Beijing Xinzhida — China's invasive BCI system for medical rehabilitation
Recent Developments
(March 2026) Neuralink patients demonstrate advanced capabilities including brain-to-text translation and playing World of Warcraft
(January 2026) Company announces 21 global trial participants and plans Blindsight vision-restoration launch
(May 2025) $650 million Series E funding round completed to expand research and scale production
(September 2024) Blindsift program receives FDA breakthrough designation for vision restoration
Open the full interactive Neuralink Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.